Can you provide information on whether CAN FITE BIOPHARMA LTD-ADR beat earnings estimates in the last quarter?
CAN FITE BIOPHARMA LTD-ADR (CANF) missed EPS estimates and missed revenue estimates in the most recent quarter.
NYSEARCA:CANF • US13471N3008
Past quarterly earnings results for CAN FITE BIOPHARMA LTD-ADR (CANF), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | - | - | 202K | - | -36.08% | |||
| Q4 2024 | -1.13 | - | -3,370.23% | 674K | 567.865K | 18.69% | 14.04% | |
| Q3 2024 | -1.13 | - | - | 567.865K | - | -22.53% | ||
| Q2 2024 | -3,744.04 | - | - | 316K | 567.865K | -44.35% | -55.80% | |
| Q1 2024 | -1.31 | - | - | 567.865K | - | 189.73% | ||
| Q4 2023 | -0.03 | -0.85 | 96.16% | - | 591K | 414.304K | 42.65% | 200.00% |
| Q3 2023 | 0.00 | -1.52 | 100.00% | 100.00% | 733K | 414.304K | 76.92% | 259.31% |
| Q2 2023 | 0.00 | -1.38 | 100.00% | 100.00% | 715K | 370.015K | 93.24% | 250.49% |
| Q1 2023 | - | - | 196K | - | -4.39% | |||
| Q4 2022 | - | - | 197K | - | -3.43% | |||
| Q3 2022 | -0.30 | - | - | 204K | - | -18.73% | ||
| Q2 2022 | -2.40 | - | - | 204K | - | -18.40% | ||
| Q1 2022 | 0.00 | - | - | 205K | - | 38.51% | ||
| Q4 2021 | - | - | 204K | - | 36.00% | |||
| Q3 2021 | - | - | 251K | - | 18.96% | |||
| Q2 2021 | - | - | 250K | - | -37.81% | |||
| Q1 2021 | - | - | 148K | - | -25.25% | |||
| Q4 2020 | - | - | 150K | - | - | |||
| Q3 2020 | - | - | 211K | - | - | |||
| Q2 2020 | - | - | 402K | - | - | |||
| Q1 2020 | - | - | 198K | - | - |
Notes
CAN FITE BIOPHARMA LTD-ADR (CANF) missed EPS estimates and missed revenue estimates in the most recent quarter.